Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Background: Immunotherapy that targets programmed death protein-1 (PD-1) provides improved treatment efficacy and survival in patients with metastatic non-small cell lung cancer (NSCLC), especially those with high tumor expression of PD-L1. However, data on this treatment are mostly from clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shu-Yung, Yang, Ching-Yao, Liao, Bin-Chi, Ho, Chao-Chi, Liao, Wei-Yu, Chen, Kuan-Yu, Tsai, Tzu-Hsiu, Hsu, Chia-Lin, Hsu, Wei-Hsun, Su, Kang-Yi, Chang, Yih-Leong, Lee, Jih-Hsiang, Lin, Chia-Chi, Shih, Jin-Yuan, Yang, James Chih-Hsin, Yu, Chong-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968770/
https://www.ncbi.nlm.nih.gov/pubmed/29805708
http://dx.doi.org/10.7150/jca.24985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968770/
https://www.ncbi.nlm.nih.gov/pubmed/29805708
http://dx.doi.org/10.7150/jca.24985

Ejemplares similares